Compugen LTD cash flow statement
In fiscal 2025, Compugen LTD's operations generated $31.6m of cash; it spent $306,000 on capital projects, leaving free cash flow of $31.3m.
Cash flow statement
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2018Dec 2018 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −7 | −4 | −11 | −6 | −11 | −26 | −20 | −13 | −28 | −23 | −34 | −36 | 50 | 32 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 2 | 2 | 2 | 4 | 4 | 4 | 3 | 2 | 3 | 4 | 4 | 4 | 3 | 2 |
| Capital spending | 0 | 0 | 1 | 0 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −8 | −4 | −12 | −7 | −13 | −29 | −22 | −13 | −28 | −23 | −35 | −36 | 49 | 31 |
| Free cash flow after stock pay | −9 | −7 | −14 | −10 | −17 | −33 | −26 | −16 | −31 | −27 | −39 | −40 | 46 | 29 |
| Shares issued | 12 | 8 | 6 | 20 | 71 | — | — | 28 | 74 | 15 | 0 | 3 | 1 | 11 |
Compare with peers
- Viridian Therapeutics, Inc.\de cash flow
- Wave Life Sciences, Inc. cash flow
- Assembly Biosciences, Inc. cash flow
- Recursion Pharmaceuticals, Inc. cash flow
- Cytokinetics Inc cash flow
Head to head: CGEN vs VRDNCGEN vs WVEASMB vs CGEN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies